BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32167701)

  • 1. Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer.
    de Freitas CSM; Soares AN
    Int Braz J Urol; 2020; 46(3):383-389. PubMed ID: 32167701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients.
    Tunn UW
    BMC Urol; 2011 Jul; 11():15. PubMed ID: 21801354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
    Ouzaid I; Rouprêt M
    Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
    Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
    Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Tolerability of Leuprorelin Acetate (Eligard®) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer.
    Ohlmann CH; Gross-Langenhoff M
    Urol Int; 2018; 100(1):66-71. PubMed ID: 29197875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.
    Spitz A; Young JM; Larsen L; Mattia-Goldberg C; Donnelly J; Chwalisz K
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):93-9. PubMed ID: 22025196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
    Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
    Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
    Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
    Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligard: leuprolide acetate in a novel sustained-release delivery system.
    Sartor O
    Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
    Fornara P; Jocham D
    Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.
    Yu EY; Getzenberg RH; Coss CC; Gittelman MM; Keane T; Tutrone R; Belkoff L; Given R; Bass J; Chu F; Gambla M; Gaylis F; Bailen J; Hancock ML; Smith J; Dalton JT; Steiner MS
    Eur Urol; 2015 Feb; 67(2):334-41. PubMed ID: 24968970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer.
    Sharifi R; Knoll LD; Smith J; Kramolowsky E
    Urology; 1998 Feb; 51(2):271-6. PubMed ID: 9495710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
    Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.
    Chang JI; Bucci J
    J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.